Over the past two decades we have been witness to a significant restructuring in phase II-III clinical developments: initially an ever increasing number of clinical pharmaceutical studies were shifted from North America to West Europe, and then from the mid-1990s to Central-Eastern Europe. And the trend continues with the involvement of new areas; ever more studies are being arranged in the developing, previously less popular regions.
However, the demand for an increasingly larger number of patients cannot be satisfied purely by involving new areas and regions. The efficient implementation of clinical studies is at least as important to the company commissioning the study, any possible clinical research organizations (CRO) involved as well as Quintiles as the market leader in the majority of areas. This is why we are working not only on expanding the range of centres taking part in clinical studies by continuously searching for new potential partners but also by placing the cooperation we have with currently active centres on new foundations. The Quintiles Partner Site Program provides the framework for this.
The objective of the Partner Site Program is to establish more effective and faster cooperation mutually advantageous both for the partner centre and for Quintiles. Naturally, the path to achieving ideal cooperation is one that involves many stages. In the course of this process Quintiles guarantees the possibility of participation in all studies in accordance with the profile of the partner centre and directly or indirectly provides assistance in resolving many administrative, organizational and training tasks. The department/hospital involved in the project helps – in compliance with a procedural order set down in a general framework contract – in the fastest possible execution of the preparatory and contracting phase, and once the study has started it ensures the required number of patients and quality of administration.